18F-Fluorodeoxyglucose positron emission/computed tomography for occult cancer among patients with unprovoked venous thromboembolism: What do we know?. Issue 213 (May 2022)

• Record Type: Journal Article
• Authors: Delluc, Aurélien; Robin, Philippe
• Is Part Of: Thrombosis research. Issue 213(2022)Supplement 1
• Page Start: S42
• Page End: S45
• Publication Date: 2022-05
• Subjects: Occult cancer -- Venous thrombosis -- PET CT; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2022.01.018
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: 18 F-Fluorodeoxyglucose Positron Emission/Computed Tomography (FDG PET/CT) is a non-invasive whole-body imaging modality that has the potential for replacing multiple cancer screening tests by one. Previous studies showed that FDG PET/CT has an excellent sensitivity and negative predictive value for occult cancer screening in patients with unprovoked venous thromboembolism (VTE). In this patient population, FDG PET/CT is a reproducible imaging procedure with a kappa value estimated at 0.75. Although false positive results may lead to unnecessary investigations, it seems from recent evidence that invasive procedures triggered by a positive scan often resulted in cancer diagnosis. Trials assessing use of FDG PET/CT for occult cancer screening in patients with VTE at high risk for occult cancer diagnosis are ongoing. Highlights: FDG PET/CT is an appealing imaging diagnostic modality for extensive occult cancer screening in patients with unprovoked VTE FDG PET/CT sensitivity and negative predictive value for occult cancer screening in unprovoked VTE are 87% and 99% VTE patients at high risk for occult cancer diagnosis may benefit form FDG PET/CT Randomized controlled trials are ongoing